PL2519231T3 - Inhibitory proteasomów do leczenia raka - Google Patents

Inhibitory proteasomów do leczenia raka

Info

Publication number
PL2519231T3
PL2519231T3 PL10807320T PL10807320T PL2519231T3 PL 2519231 T3 PL2519231 T3 PL 2519231T3 PL 10807320 T PL10807320 T PL 10807320T PL 10807320 T PL10807320 T PL 10807320T PL 2519231 T3 PL2519231 T3 PL 2519231T3
Authority
PL
Poland
Prior art keywords
treating cancer
proteasome inhibitors
proteasome
inhibitors
cancer
Prior art date
Application number
PL10807320T
Other languages
English (en)
Inventor
Coster Roland De
De Velde Helgi Van
Martine Bayssas
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43629456&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2519231(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of PL2519231T3 publication Critical patent/PL2519231T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/69Boron compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL10807320T 2009-10-01 2010-10-01 Inhibitory proteasomów do leczenia raka PL2519231T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US24771409P 2009-10-01 2009-10-01

Publications (1)

Publication Number Publication Date
PL2519231T3 true PL2519231T3 (pl) 2017-09-29

Family

ID=43629456

Family Applications (1)

Application Number Title Priority Date Filing Date
PL10807320T PL2519231T3 (pl) 2009-10-01 2010-10-01 Inhibitory proteasomów do leczenia raka

Country Status (17)

Country Link
US (1) US20110189204A1 (pl)
EP (1) EP2519231B1 (pl)
JP (1) JP2013506626A (pl)
AU (2) AU2010300259A1 (pl)
CA (1) CA2776327A1 (pl)
CY (1) CY1118925T1 (pl)
DK (1) DK2519231T3 (pl)
ES (1) ES2624644T3 (pl)
HR (1) HRP20170702T1 (pl)
HU (1) HUE032571T2 (pl)
LT (1) LT2519231T (pl)
ME (1) ME02725B (pl)
PL (1) PL2519231T3 (pl)
PT (1) PT2519231T (pl)
RS (1) RS55931B1 (pl)
SI (1) SI2519231T1 (pl)
WO (1) WO2011038924A2 (pl)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2855356A1 (en) * 2011-11-11 2013-05-16 Millennium Pharmaceuticals, Inc. Biomarkers of response to proteasome inhibitors
JP6592097B2 (ja) * 2014-10-30 2019-10-16 ビッグ ディーエヌエイ リミテッドBig Dna Ltd 併用療法
US20180296531A1 (en) * 2015-10-20 2018-10-18 The Cleveland Clinic Foundation Stimulation of 11b-hsd2 expression to improve hormonal therapy of steroid-dependent disease

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4499802A (en) * 1982-09-29 1985-02-19 Container Graphics Corporation Rotary cutting die with scrap ejection
US4537773A (en) 1983-12-05 1985-08-27 E. I. Du Pont De Nemours And Company α-Aminoboronic acid derivatives
US4499082A (en) 1983-12-05 1985-02-12 E. I. Du Pont De Nemours And Company α-Aminoboronic acid peptides
US5081110A (en) * 1986-03-27 1992-01-14 Sloan-Kettering Institute For Cancer Research Method of killing sarcoma cells using fludarabine phosphate and ionizing radiation
US6083903A (en) * 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
WO2000047230A1 (fr) * 1999-02-10 2000-08-17 The Kitasato Institute Potentialisateurs d'agent anticancereux
EP3078667B1 (en) 2001-01-25 2018-11-21 The United States of America, represented by the Secretary, Department of Health and Human Services Formulation of boronic acid compounds
WO2006077428A1 (en) 2005-01-21 2006-07-27 Astex Therapeutics Limited Pharmaceutical compounds
JP2008528469A (ja) 2005-01-21 2008-07-31 アステックス・セラピューティクス・リミテッド ピラゾールキナーゼ阻害剤およびさらなる抗癌剤の組合せ剤
US20060193844A1 (en) * 2005-02-28 2006-08-31 Proteolix, Inc. Methods for enzyme inhibition
ATE553198T1 (de) 2005-04-15 2012-04-15 Geron Corp Behandlung von krebs durch die kombinierte hemmung der proteasom- und telomeraseaktivitäten
WO2008086005A1 (en) * 2007-01-09 2008-07-17 University Of South Florida Compositions including triciribine and bortezomib and derivatives thereof and methods of use thereof
MX2010002179A (es) * 2007-08-24 2010-04-27 Stichting Het Nl Kanker I Composicion para el tratamiento de enfermedades neoplasicas.

Also Published As

Publication number Publication date
HRP20170702T1 (hr) 2017-07-14
CA2776327A1 (en) 2011-04-07
SI2519231T1 (sl) 2017-07-31
RS55931B1 (sr) 2017-09-29
WO2011038924A9 (en) 2011-07-14
HUE032571T2 (en) 2017-09-28
JP2013506626A (ja) 2013-02-28
EP2519231A2 (en) 2012-11-07
AU2010300259A1 (en) 2012-04-26
US20110189204A1 (en) 2011-08-04
LT2519231T (lt) 2017-05-10
ES2624644T3 (es) 2017-07-17
DK2519231T3 (en) 2017-06-26
WO2011038924A2 (en) 2011-04-07
ME02725B (me) 2017-10-20
AU2016277700A1 (en) 2017-02-02
EP2519231B1 (en) 2017-03-15
WO2011038924A3 (en) 2011-05-26
PT2519231T (pt) 2017-05-25
CY1118925T1 (el) 2018-01-10

Similar Documents

Publication Publication Date Title
HK1200363A1 (en) Compounds useful for treating cancer
HUE060305T2 (hu) FAP-aktivált proteaszóma inhibitorok a szolid tumorok kezelésére
HK1175476A1 (en) Cancer treatment
IL218987A0 (en) Methods and compositions for treating cancer
ZA201205004B (en) Methods for treating pancreatic cancer
EP2461835A4 (en) COMPOSITIONS WITH JARID1B INHIBITORS AND METHOD FOR THE TREATMENT OF CANCER
EP2424516A4 (en) PENTAMIDINE COMBINATIONS FOR THE TREATMENT OF CANCER
EP2635286A4 (en) METHOD FOR THE TREATMENT OF CANCER
EP2419136A4 (en) COMPOSITIONS AND METHOD FOR THE TREATMENT OF CANCER
IL196208A0 (en) Methods for cancer treatment using tak1 inhibitors
IL218230A0 (en) Method of treating cancer
EP2768512A4 (en) ENZYME HAMMER FOR CANCER TREATMENT
EP2560648A4 (en) METHOD OF TREATING PANCREATIC CANCER
PL2519231T3 (pl) Inhibitory proteasomów do leczenia raka
ZA201201894B (en) Pharmaceutical combination for treating tumor
PT2509599E (pt) Processo para o tratamento de cancro pancreático
EP2250290A4 (en) PTTG1 AS A BIOMARKER FOR CANCER TREATMENT
IL215199A0 (en) Thia-triaza-cyclopentazulenes as pi3-kinases inhibitors for the treatment of cancer
EP2403963A4 (en) BIOMARKER AND TREATMENT FOR CANCER
GB0914322D0 (en) Compounds for treating cancer
GB201019034D0 (en) Treatment for tumors